Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 2018

View Archived Issues

Targeting Mdf could inhibit the evolution of antimicrobial resistance

Cation channel TRPV1 identified as a therapeutic target for cardiac hypertrophy and heart failure

RIP1 is an immune checkpoint kinase conferring immunotherapy resistance in pancreatic ductal cancer

BET bromodomain inhibitors destress ALS cells

Alpha-synuclein derails lipid metabolism

BCL6 unveiled as a novel therapeutic target for triple-negative breast cancer

BRG1-SOX4 drives oncogenic signaling in triple-negative breast cancer

CDC20 emerges as a novel target for triple-negative breast cancer

Metastasis of triple-negative breast cancer is controlled by PEA15 phosphorylation

In MDS and AML, many bad seeds

Vanda presents promising data from pivotal study of tasimelteon in Smith-Magenis syndrome

Phase II study of zilucoplan in gMG meets primary and key secondary endpoints

Phase II study of serlopitant demonstrates reduction of pruritus associated with psoriasis

Phase I study of silmitasertib shows promise in patients with cholangiocarcinoma

Oppilan Pharma presents sphingosine 1-phosphate receptor 1 agonists

LegoChem Biosciences patents E-NPP 2 inhibitors

WDR5/MLL1 interaction inhibitors identified at the University of Michigan

Prescient Therapeutics reports interim durability data on PTX-200 in breast cancer

Vanderbilt University synthesizes RAS GTPase inhibitors

Shionogi and Ube establish strategic research collaboration in RSV

Arctic Pharma discovers lactate dehydrogenase A inhibitors

Immix reports interim findings from phase Ib/IIa study of IMX-110 in advanced solid tumors

Itanapraced demonstrates animal proof of concept in Parkinson's disease models

Axovant reports exploratory phase II study results for nelotanserin

Marinus reports interim phase II data with intravenous and oral ganaxolone in postpartum depression

Constellation advances ProSTAR trial of CPI-1205 in metastatic CRPC into phase II

IDMC recommends continuation of phase II/III trial of AXS-05 in Alzheimer's disease agitation

Cantargia presents update on its CANFOUR study of CAN-04

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 16, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...